☆ 4.7 Editorial Material

Commentary: Novel therapies for cancer: Why dirty might be better

ONCOLOGIST (2008)

Get Full Text
Add to Collection

Journal

ONCOLOGIST
Volume 13, Issue 3, Pages 277-283

Publisher

ALPHAMED PRESS
DOI: 10.1634/theoncologist.2007-0090

Keywords

targeted agents; drug resistance; tyrosine kinase inhibitors; imatinib; Bcr-Abl; c-KIT; epidermal growth factor receptor (EGFR) inhibitors; gefitinib; erlotinib; stem cells

Categories

Oncology

Funding

  1. NATIONAL CANCER INSTITUTE [ZIABC010625, Z01SC006732, Z01BC010625, ZIASC006732] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.